Drug intelligence / Profile preview

AIG-Immune1

Development stage: Unknown
Lead developer: Lmito Therapeutics
Modality: Small Molecules

Overview

AIG-Immune1 is a small molecule drug that was initially developed by Lmito Therapeutics and Aigen Sciences. It has been investigated for the treatment of immune system diseases, with autoimmune diseases listed as an inactive indication. The drug reached the discovery phase in development but has since been discontinued. Specific details regarding its mechanism of action, molecular target, or chemical structure have not been disclosed in public sources as of June 2025[4].

Beyond the preview

Go deeper on AIG-Immune1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIG-Immune1.

Explore the full profile